FB23-2

Catalog No.S8837 Batch:S883703

Technical Data

Formula

C₁₈H₁₅Cl₂N₃O₃

Molecular Weight

392.24

CAS No.

2243736-45-8

Solubility (25°C)*

In vitro

DMSO

Insoluble

Water

Insoluble

Ethanol

Insoluble

In vivo (Add solvents to the product individually and in order)

Clear solution

5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O

4.0mg/ml

Taking the 1 mL working solution as an example, add 50 μL of 80 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

FB23-2 is a potent and selective FTO inhibitor that directly binds to FTO and selectively inhibits FTO's N⁶-methyladenosine (m⁶A) demethylase activity with IC50 of 2.6 μM.

Targets

FTO ^[1]
(Cell-free assay)

2.6 μM

In vitro

FB23-2 directly binds to FTO and selectively inhibits FTO’s m⁶A demethylase activity. Mimicking FTO depletion, FB23-2 dramatically suppresses proliferation and promotes the differentiation/apoptosis of human acute myeloid leukemia (AML) cell line cells and primary blast AML cells in vitro.^[1]

In vivo

FB23-2 significantly inhibits the progression of human AML cell lines and primary cells in xeno-transplanted mice.^[1]

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines Leukemia cells NB4, U937, MV4-11, ML-2; MONOMAC6 (ACC-124) cells; 293T cells; The mouse bone marrow cells FLT3ITD/NPM1, MA9 Concentrations 10 μM, 5 μM Incubation Time 24 h, 72 h Method NB4 and MONOMAC6 cells are treated with DMSO or FB23-2 at varying concentrations for 72 h, while MA9 and FLT3/NPM1 primary cells isolated from AML mice, five human AML cell (MA9.3ITD, MA9.3RAS, U937, ML2, and MV4-11), and human primary AML cells are treated with DMSO or 5 μM FB23-2 for 72 h for dot blot assay.
Animal Study:^{^[1]}	Animal Models NSGS mice with xeno-transplantation model Dosages 2 mg/kg Administration IP

Cell Assay:^{^[1]}

Cell lines
Leukemia cells NB4, U937, MV4-11, ML-2; MONOMAC6 (ACC-124) cells; 293T cells; The mouse bone marrow cells FLT3ITD/NPM1, MA9
Concentrations
10 μM, 5 μM
Incubation Time
24 h, 72 h
Method
NB4 and MONOMAC6 cells are treated with DMSO or FB23-2 at varying concentrations for 72 h, while MA9 and FLT3/NPM1 primary cells isolated from AML mice, five human AML cell (MA9.3ITD, MA9.3RAS, U937, ML2, and MV4-11), and human primary AML cells are treated with DMSO or 5 μM FB23-2 for 72 h for dot blot assay.

Animal Study:^{^[1]}

Animal Models
NSGS mice with xeno-transplantation model
Dosages
2 mg/kg
Administration
IP

References

[1] Yue Huang, et al. Cancer Cell. 2019 Apr 15;35(4):677-691.e10.

Selleck's FB23-2 has been cited by 6 publications

YTHDF2 upregulation and subcellular localization dictate CD8 T cell polyfunctionality in anti-tumor immunity [ Nat Commun, 2024, 15(1):9559]	PubMed: 39500904
m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway [ J Exp Clin Cancer Res, 2023, 42(1):217]	PubMed: 37605223
Targeting AKT induced Ferroptosis through FTO/YTHDF2-dependent GPX4 m6A methylation up-regulating and degradating in colorectal cancer [ Cell Death Discov, 2023, 9(1):457]	PubMed: 38102129
Cytoplasmic Expression of TP53INP2 Modulated by Demethylase FTO and Mutant NPM1 Promotes Autophagy in Leukemia Cells [ Int J Mol Sci, 2023, 24(2)1624]	PubMed: 36675134
m6A demethylase FTO renders radioresistance of nasopharyngeal carcinoma via promoting OTUB1-mediated anti-ferroptosis [ Transl Oncol, 2023, 27:101576]	PubMed: 36343416
E6E7 regulates the HK2 expression in cervical cancer via GSK3β/FTO signal [ Arch Biochem Biophys, 2022, 729:109389]	PubMed: 36075458

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.